A 24-Week Prospective, Multicenter, Real-World Study on Eptinezumab’s Effectiveness and Safety in Migraine Prevention (EMBRACE II)
Piero Barbanti,Cinzia Aurilia,Gabriella Egeo,Alberto Doretti, Florindo d’Onofrio, Paola Scatena, Steno Rinalduzzi, Luisa Vinciguerra, Mattia Sansone, Rosario Vecchio, Valeria Drago,Giovanna Viticchi,Marco Bartolini,Angelo Ranieri, Monica Bandettini di Poggio, Francesco Baldisseri,Davide Mascarella, Fabio Brusaferri, Luigi Caputi,Stefano Messina,Massimo Autunno, Alessandro Valenza,Bianca Orlando, Marisa Distefano, Laura Borrello,Francesca Pistoia,Cecilia Camarda,Gennaro Saporito, Giacomo Querzola,Paola Torelli,Antonio Salerno, Francesca Gragnani,Barbara Petolicchio,Antonio Carnevale,Roberta Messina,Massimo Filippi, Sofia Tavani, Giulia Fiorentini,Stefano Bonassi,Sabina Cevoli, Alice Mannocci Journal of Neurology（2025）
Key words
Eptinezumab,CGRP,Migraine,Treatment,Real-world,Disability
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper